ANI Pharmaceuticals, Inc.
Bear Case (25th pct.)
-20.0% vs price
Base Case (Median)
15.6% vs price
Bull Case (75th pct.)
35.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $68.66 | -9.7% | High (40%) |
| PE Comparable | $103.04 | 35.6% | Medium (25%) |
| Growth Trajectory DCF | $87.85 | 15.6% | Medium (20%) |
| Graham Number | $53.00 | -30.3% | Medium (40%) |
| EV/EBITDA | $103.36 | 36.0% | Medium (20%) |
| EV/FCF | $159.02 | 109.2% | Medium (20%) |
| Earnings Power Value | $31.45 | -58.6% | Medium (50%) |
Based on 7 out of 8 methods, ANIP appears fairly valued at the current price of $76.00. The base case fair value of $87.85 implies 15.6% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.